ANTHRANILIC ACID AND THIOANTHRANILIC ACID N-ARYLAMIDES

FIELD: organic chemistry, medicine, biochemistry, pharmacy. ^ SUBSTANCE: invention relates to benzamide derivatives possessing with inhibitory activity with respect to tyrosine kinase Flt-1-receptors VEGF that can be used in treatment of neoplastic disease. Invention describes a pharmaceutical subst...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BOL'D GUIDO, VUD ZHANETTA MARZHORI, MESTAN JURGEN, FERRARI STEFANO, KRUGER MARTIN, KHABERI MARTIN, TIRAUKH KARL-KHAJNTS, AL'TMANN KARL-KHAJNTS, MANLI POL UILL'JAM, KHUT ANDREAS, FJURE PASKAL, MENRAD ANDREAS, KHOFMANN FRANCHESKO, SAJDEL'MANN DITER
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: organic chemistry, medicine, biochemistry, pharmacy. ^ SUBSTANCE: invention relates to benzamide derivatives possessing with inhibitory activity with respect to tyrosine kinase Flt-1-receptors VEGF that can be used in treatment of neoplastic disease. Invention describes a pharmaceutical substance comprising compounds of the group 2-[(4-pyridyl)methyl]-amino-N-[R1]-benzamide wherein R1 means 4-chlorophenyl, 4-methylphenyl, 4-chloro-3-(trifluoromethyl)phenyl or 3-(trifluoromethyl)phenyl possessing with the inhibitory activity with respect to tyrosine kinase Flt5-2-receptors VEGF associated with neoplastic disease and angiogenesis. Also, invention describes novel compounds of the group 2-[(nitrogen-containing heterocycle)methyl]-amino-N-[R1]-benzamide wherein nitrogen-containing heterocycle is represented by 4-pyrodyl, 4- or 5-quinolinyl, 2-imidazolyl, and a method for their synthesis. Also, invention describes a pharmaceutical composition comprising abovementioned compounds possessing the inhibitory activity with respect to tyrosine kinase VEGF receptors used in treatment of neoplastic disease. ^ EFFECT: valuable medicinal properties of compounds and pharmaceutical composition. ^ 17 cl, 2 tbl, 74 ex